Skip to main content
  1. Right Decisions
  2. DGRefHelp - NHS Dumfries & Galloway
  3. Sexual health
  4. Contraception
  5. Back
  6. Progesterone only implant
  7. Follow up, removal, and management of problems
Important: please update your RDS app to version 4.7.3 Details with newsletter below.

Please update your RDS app to v4.7.3

We asked you in January to update to v4.7.2.  After the deployment planned for 27th February, this new update will be needed to ensure that you are able to download RDS toolkits even when the RDS website is not available. We will wait until as many users as possible have downloaded the new version before switching off the old system for app downloads and moving entirely to the new approach.

To check your current RDS version, click on the three dots bottom right of the RDS app screen. This takes you to a “More” page where you will see the version number. 

To update to the latest release:

 On iPhones – go to the Apple store, click on your profile icon top right, scroll down to see the apps waiting to be updated and update the RDS app.

On Android phones – these can vary, but try going to the Google Play store, click on your profile icon top right, click on “Manage apps and device”, select and update the RDS app.

Right Decision Service newsletter: February 2025

Welcome to the February 2025 update from the RDS team

1.     Next release of RDS

 

A new release of RDS is planned (subject to outcomes of current testing) for week beginning 24th February. This will deliver:

 

  • Fixes to mitigate the recurring glitches with the RDS admin area and the occasional brief user interface outages which have arisen following implementation of the new distributed technology infrastructure in December 2024.

 

  • Capability to embed content from Google calendar, Google Maps, Daily Motion, Twitter feeds, Microsoft Stream into RDS pages.

 

  • Capability to include simple multiplication in RDS calculators.

 

The release will also incorporate a number of small fixes, including:

  • Exporting of form within Medicines Sick Day Guidance in polypharmacy toolkit
  • Links to redundant content appearing in search in some RDS toolkits
  • Inclusion of accordion headers alongside accordion text in search result snippets.
  • Feedback form on mobile app.
  • Internal links on mobile app version of benzo tapering tool

 

We will let you know when the date and time for the new release are confirmed.

 

2.     New RDS developments

There is now the capability to publish toolkits on the web with left hand side navigation rather than tiles on the homepage. To use this feature, turn on the “Toggle navigation panel” option at the top of the Page settings menu at toolkit homepage level – see below. Please note that publication to downloadable mobile app for this type of navigation is still under development.

The Benzodiazepine tapering tool (https://rightdecisions.scot.nhs.uk/benzotapering) is now available as part of the RDS toolkit for the national benzodiazepine prescribing guidance developed by the Scottish Government Effective Prescribing team. The tool uses this national guidance developed with a wide-ranging multidisciplinary group. This should be used in combination with professional judgement and an understanding of the needs of the individual patient.

3.     Archiving and version control and new RDS Search and Browse interface

Due to the intensive work Tactuum has had to undertake on the new technology infrastructure has pushed back the delivery dates again and some new requirements have come out of the recent user acceptance testing. It now looks likely to be an April release for the search and browse interface. The archiving and version control functionality may be released earlier. We’ll keep you posted.

4.     Statistics

At the end of January, Olivia completed the generation of the latest set of usage statistics for all RDS toolkits. If you would like a copy of the stats for your toolkit, please contact Olivia.graham@nhs.scot .

 

5.     Review of content past its review date

We have now generated reports of all RDS toolkit content that has exceeded its review date by 6 months or more. We will be in touch later this month with toolkit owners and editors to agree the plan for updating or withdrawing out of date content.

 

6.     Toolkits in development

Some important toolkits in development by the RDS team include:

  • National CVD prevention pathways – due for release end of March 2025.
  • National respiratory pathways, optimal cancer diagnostic pathways and cancer prehabilitation pathways from the Centre for Sustainable Delivery. We will shortly start work on the national cancer referral pathways, first version due for release via RDS around end of June 2025.
  • HIS Quality of Care Review toolkit – currently in final stages of quality assurance.

 

The RDS team and other information scientists in HIS have also been producing evidence summaries for the Scottish Government Realistic Medicine team, to inform development of national guidance around Procedures of Limited Clinical Value. This guidance will in due course be translated into an RDS toolkit.

 

7. Training sessions for new editors (also serve as refresher sessions for existing editors) will take place on the following dates:

  • Friday 28th February 12-1 pm
  • Tuesday 11th March 4-5 pm

 

To book a place, please contact Olivia.graham@nhs.scot, providing your name, organisation, job role, and level of experience with RDS editing (none, a little, moderate, extensive.)

 

To invite colleagues to sign up to receive this newsletter, please signpost them to the registration form  - also available in End-user and Provider sections of the RDS Learning and Support area.   If you have any questions about the content of this newsletter, please contact his.decisionsupport@nhs.scot  If you would prefer not to receive future newsletters, please email Olivia.graham@nhs.scot and ask to be removed from the circulation list.

With kind regards

 

Right Decision Service team

Healthcare Improvement Scotland

 

 

Follow up, removal, and management of problems

Warning

Post-insertion instructions & follow up arrangements

  • Advise additional contraception for seven days if necessary.
  • Give wound care instructions at time of insertion.
  • Advise to take simple analgesia if required.
  • Routine post-insertion follow up is not necessary. Women should be advised to return at any time to discuss problems or if they want to change their contraceptive method.
  • Advise women to return if they:
    • cannot feel the implant
    • notice any change in shape or changes to the skin around the site of the implant
    • experience any pain
    • become pregnant or develop any condition that would contraindicate its use.

Removal

Timing of removal

Implants work by preventing ovulation. Contraceptive cover is present until the device is removed, irrespective of when last sexual intercourse occurred. Any sexual intercourse after removal must be covered by an alternative method of contraception if pregnancy is to be avoided.

 

Timing of change

If an implant is removed prior to its licence limit (3 years) and another implant reinserted immediately, there is no need for additional contraceptive precautions.

An implant that has been in situ between 3 and 4 years can be changed if a pregnancy test is negative. If there has been UPSI in the past 3 weeks a repeat pregnancy test should be considered 21 days after the UPSI.

 

Management of problems

Management of bleeding problems with progesterone implants

  • A sexual history should be taken from women who experience unacceptable bleeding while using the implant to establish STI risk.
  • Investigation for gynaecological pathology may be clinically indicated, i.e., inspection of the cervix is recommended to exclude local causes.
  • Only perform a cervical smear test if it is due.
  • There is very little evidence supporting the use of any particular drug regimen in the management of persistent unacceptable bleeding patterns with implant use. Women who are eligible may be offered a COC cyclically or continuously for 3 months (outwith the product Licence).

If other pathology is excluded or treated, the client can be reassured that irregular bleeding patterns is an expected side effect of an implant, but she should report any further changes.

Deep implant/Lost implant

Women with an impalpable implant should be advised to use additional precautions or avoid intercourse until presence of the implant is confirmed.

If the implant is impalpable, no attempt should be made to remove it. The client should be referred for ultrasound location.

High frequency linear ultrasound remains the recommended first line imaging technique for locating a non palpable or deep implant. Nexplanon is radio-opaque and can be seen on X-ray.

Deeply inserted implants may need to be removed by an expert and should be referred to the local expert removal centre.

If after imaging the implant cannot be located then advice from a Senior Clinician should be sought to see whether blood levels for etonorgestrel need performed.

 

Editorial Information

Last reviewed: 31/05/2024

Next review date: 31/05/2026

Author(s): West of Scotland Managed Clinical Network for Sexual Health Clinical Guidelines Group .

Version: 9.1

Approved By: West of Scotland Managed Clinical Network for Sexual Health